Apollomics (APLM) AI Stock Analysis

• Market Cap: $8.01M
• Dividend Yield: N/A
• Average Volume (3M): 20.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: N/A
• EPS Growth: -1786.46%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -16.91
• Shares Outstanding: 1,103,348
• 10 Day Avg. Volume: 10,461
• 30 Day Avg. Volume: 20,078
• PEG Ratio: -0.18
• Price to Book (P/B): 108.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.25
• Enterprise Value/Market Cap: -0.32
• Enterprise Value/Revenue: -0.49
• Enterprise Value/Gross Profit: -1.12
• Enterprise Value/Ebitda: 0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Apollomics' stock score is primarily impacted by its financial instability, characterized by persistent losses and high leverage. While there are slight technical indicators of improvement, the negative P/E ratio and absence of dividends present valuation challenges. Overall, the stock's speculative nature and financial concerns result in a low score.

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

How the Company Makes Money

Apollomics primarily generates revenue through the development and commercialization of its oncology drug candidates. The company's revenue streams include milestone payments and royalties from partnerships with other pharmaceutical companies. Additionally, Apollomics may generate income from licensing its proprietary technologies and intellectual property to third parties. Significant partnerships with larger pharmaceutical firms can provide funding for drug development and potential co-marketing opportunities, contributing to its earnings.

Apollomics Financial Statement Overview

Summary

Apollomics faces significant financial challenges with persistent losses, high leverage, and negative cash flows. Though there are slight improvements in equity and revenue growth, profitability and cash flow generation remain critical areas for improvement.

Income Statement

Apollomics shows a consistent pattern of negative profitability with significant net losses over multiple years. The company reported a negative gross profit margin and declining EBIT and EBITDA margins. While there is revenue growth from 2022 to 2023, the overall financial health in terms of profitability remains weak.

Balance Sheet

The balance sheet indicates a high level of liabilities relative to equity, resulting in a negative debt-to-equity ratio historically. Although the equity improved to positive in 2023, which is a positive sign, the overall leverage remains a concern. The equity ratio is relatively low for the biotechnology industry, suggesting potential financial instability.

Cash Flow

Cash flows are challenging, with negative operating cash flow and free cash flow across the years. There was a slight improvement in 2023's free cash flow growth rate, but the operating cash flow to net income ratio indicates inefficiencies in turning income into cash. Cash flow management remains a crucial area for improvement.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.27M	0.00	821.00K	323.00K	2.00K	1.84M
	Gross Profit
2.27M	0.00	127.00K	-452.00K	-679.00K	1.23M
	EBIT
-53.01M	-42.33M	-54.83M	-240.21M	-91.75M	-74.08M
	EBITDA
-53.02M	-53.42M	-171.75M	-239.94M	-94.03M	-74.22M
	Net Income Common Stockholders
-57.11M	-53.86M	-172.60M	-240.81M	-94.80M	-74.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
154.51M	9.77M	37.82M	54.61M	94.48M	154.39M
	Total Assets
0.00	13.10M	55.39M	76.47M	123.44M	169.94M
	Total Debt
0.00	966.00K	4.66M	991.00K	1.04M	1.51M
	Net Debt
154.51M	-8.80M	-27.39M	-31.68M	-45.70M	-129.13M
	Total Liabilities
0.00	8.23M	14.15M	524.60M	336.30M	297.87M
	Stockholders Equity
-127.93M	4.86M	41.23M	-448.12M	-212.86M	-127.93M
Cash Flow		Free Cash Flow
-34.82M	-28.77M	-43.22M	-43.19M	-50.86M	-45.83M
	Operating Cash Flow
-34.80M	-28.74M	-43.21M	-42.82M	-43.31M	-35.68M
	Investing Cash Flow
27.35M	5.98M	21.36M	29.05M	-38.95M	2.33M
	Financing Cash Flow
8.10M	468.00K	21.23M	-294.00K	-1.64M	125.51M

Apollomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Positive. The current price of 7.26 is above the 20-day moving average (MA) of 5.89, above the 50-day MA of 6.56, and below the 200-day MA of 9.91, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.54 is Neutral, neither overbought nor oversold. The STOCH value of 79.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APLM.

Apollomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
APLM	42 Neutral	$8.01M	―	-233.67%	―	―	-1786.46%
SNGX	39 Underperform	$5.91M	―	-437.73%	―	―	57.83%
SLXN	34 Underperform	$9.04M	―	-590.37%	―	―	-73095.97%
MTVA	33 Underperform	$15.45M	―	-339.64%	―	―	-75.88%
RNAZ	27 Underperform	$6.35M	―	-342.99%	―	―	99.64%
LIPO		$12.96M	―	-154.54%	―	―	―